TCT 2023 | SWEDEHEART, Evolution at 5 Years

This register included 42,887 patients receiving FFR or iFR to assess moderate lesions, and 80% of them underwent FFR.

TCT 2023 | SWEDEHEART, evolución  a 5 años

Population characteristics were similar, except that the iFR group had more women, with more diabetes, MI, stroke and chronic obstructive pulmonary disease (COPD).

Primary end point was a composite of all cause death, MI and unplanned revascularization.

At 5 years, there were no significant differences in primary end point, or individual events, which include all cause death, MI and unplanned revascularization. Also, MACE were analyzed in treated and deferred patients, with no differences neither in MACE nor in individual events. 

At group sub-analyzis, no differences were found either, between FFR and iFR patients. 

Read also: TCT 2023 | EVOLUT Low Risk: 4-Year Follow-up.

In conclusion, the authors determined that, at 5 years, there were no significant differences in MACE or in the events of all cause death, MI and unplanned revascularization. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the editorial board of SOLACI.org.

Presented by Matthias Götberg during TCT 2023.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

*

Top